Study to contain antimicrobial resistant neonatal sepsis begins in India (NeoSep 1 trial expansion)
An international neonatal sepsis trial has been expanded in India to test antibiotic combinations against drug-resistant infections in newborns.
What happened
An international clinical trial, NeoSep 1, has expanded to India to study better treatment for neonatal sepsis in the context of rising antimicrobial resistance. The trial is coordinated by GARDP with partners including UCL’s Innovative Clinical Trials Unit, City St George’s, and Penta Foundation.
Indian enrolment has started at JIPMER, Puducherry and Pt. B.D. Sharma PGIMS, Rohtak, with further recruitment planned at Lokmanya Tilak Municipal College and General Hospital, Mumbai. The trial is already running in Vietnam and Pakistan, and is expected to begin soon in Malaysia, Bangladesh and Uganda.
UPSC may ask how India should respond to neonatal mortality driven by drug-resistant infections. The issue connects epidemiology, rational antibiotic policy, clinical trial design, and the need for India-specific evidence in public health decision-making.
